BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 23261227)

  • 21. Value of ¹⁸F-FDG uptake on PET/CT and CEA level to predict epidermal growth factor receptor mutations in pulmonary adenocarcinoma.
    Ko KH; Hsu HH; Huang TW; Gao HW; Shen DH; Chang WC; Hsu YC; Chang TH; Chu CM; Ho CL; Chang H
    Eur J Nucl Med Mol Imaging; 2014 Oct; 41(10):1889-97. PubMed ID: 24852187
    [TBL] [Abstract][Full Text] [Related]  

  • 22. ALK-rearranged pulmonary adenocarcinoma in Thai Patients: From diagnosis to treatment efficacy.
    Incharoen P; Reungwetwattana T; Saowapa S; Kamprerasart K; Pangpunyakulchai D; Arsa L; Jinawath A
    World J Surg Oncol; 2016 May; 14():139. PubMed ID: 27142166
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lung cancers with concomitant EGFR mutations and ALK rearrangements: diverse responses to EGFR-TKI and crizotinib in relation to diverse receptors phosphorylation.
    Yang JJ; Zhang XC; Su J; Xu CR; Zhou Q; Tian HX; Xie Z; Chen HJ; Huang YS; Jiang BY; Wang Z; Wang BC; Yang XN; Zhong WZ; Nie Q; Liao RQ; Mok TS; Wu YL
    Clin Cancer Res; 2014 Mar; 20(5):1383-92. PubMed ID: 24443522
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The role of (18)F-FDG PET/CT for evaluation of metastatic mediastinal lymph nodes in patients with lung squamous-cell carcinoma or adenocarcinoma.
    Lu P; Sun Y; Sun Y; Yu L
    Lung Cancer; 2014 Jul; 85(1):53-8. PubMed ID: 24792334
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Detection of ALK gene rearrangement in non-small cell lung cancer: a comparison of fluorescence in situ hybridization and chromogenic in situ hybridization with correlation of ALK protein expression.
    Kim H; Yoo SB; Choe JY; Paik JH; Xu X; Nitta H; Zhang W; Grogan TM; Lee CT; Jheon S; Chung JH
    J Thorac Oncol; 2011 Aug; 6(8):1359-66. PubMed ID: 21587085
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical characteristics associated with ALK rearrangements in never-smokers with pulmonary adenocarcinoma.
    Sun JM; Lira M; Pandya K; Choi YL; Ahn JS; Mao M; Han J; Park K; Ahn MJ; Kim J
    Lung Cancer; 2014 Feb; 83(2):259-64. PubMed ID: 24300132
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Differential diagnosis between (18)F-FDG-avid metastatic lymph nodes in non-small cell lung cancer and benign nodes on dual-time point PET/CT scan.
    Suga K; Kawakami Y; Hiyama A; Sugi K; Okabe K; Matsumoto T; Ueda K; Tanaka N; Matsunaga N
    Ann Nucl Med; 2009 Aug; 23(6):523-31. PubMed ID: 19444550
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical and CT characteristics of surgically resected lung adenocarcinomas harboring ALK rearrangements or EGFR mutations.
    Wang H; Schabath MB; Liu Y; Han Y; Li Q; Gillies RJ; Ye Z
    Eur J Radiol; 2016 Nov; 85(11):1934-1940. PubMed ID: 27776643
    [TBL] [Abstract][Full Text] [Related]  

  • 29. FDG-PET SUV-max values do not correlate with epidermal growth factor receptor mutation status in lung adenocarcinoma.
    Putora PM; Früh M; Müller J
    Respirology; 2013 May; 18(4):734-5. PubMed ID: 23489365
    [TBL] [Abstract][Full Text] [Related]  

  • 30. F18-FDG PET-CT analyses of small peripheral adenocarcinoma of the lung.
    Takahashi Y; Takashima S; Watanabe S; Tomita Y; Hakucho T; Miyake C; Morimoto D; Hosoki T; Nakanishi K; Higashiyama M
    Acta Radiol; 2013 Mar; 54(2):164-8. PubMed ID: 23138022
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Correlation of early PET findings with tumor response to molecular targeted agents in patients with advanced driver-mutated non-small cell lung cancer.
    Koizumi T; Fukushima T; Gomi D; Kobayashi T; Sekiguchi N; Mamiya K; Tateishi K; Katou A; Oguchi K
    Med Oncol; 2017 Sep; 34(10):169. PubMed ID: 28864950
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Evaluate the value of (18)F-FDG PET-CT imaging in predicting the mutationsin epidermal growth factor receptor in lung adenocarcinoma].
    Ding CY; Yang WP; Guo Z; Sun J; Li YY; Li TR
    Zhonghua Zhong Liu Za Zhi; 2017 Jul; 39(7):528-531. PubMed ID: 28728300
    [No Abstract]   [Full Text] [Related]  

  • 33. Distinct features of distant metastasis and lymph node stage in lung adenocarcinoma patients with epidermal growth factor receptor gene mutations.
    Enomoto Y; Takada K; Hagiwara E; Kojima E
    Respir Investig; 2013 Sep; 51(3):153-7. PubMed ID: 23978641
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Prognostic value of PET/CT in lung cancer: retrospective analysis of 47 patients].
    de Guevara DL; Fuentes A; Fariña C; Corral C; Pefaur R
    Rev Med Chil; 2013 Jan; 141(1):41-8. PubMed ID: 23732413
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic significance of genotype and number of metastatic sites in advanced non-small-cell lung cancer.
    He YY; Zhang XC; Yang JJ; Niu FY; Zeng Z; Yan HH; Xu CR; Guan JL; Zhong WZ; Yang LL; Guo LH; Wu YL
    Clin Lung Cancer; 2014 Nov; 15(6):441-7. PubMed ID: 25044104
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Relationship between maximum standardized uptake value (SUVmax) of lung cancer and lymph node metastasis on FDG-PET.
    Nambu A; Kato S; Sato Y; Okuwaki H; Nishikawa K; Saito A; Matsumoto K; Ichikawa T; Araki T
    Ann Nucl Med; 2009 May; 23(3):269-75. PubMed ID: 19340527
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anaplastic lymphoma kinase translocation: a predictive biomarker of pemetrexed in patients with non-small cell lung cancer.
    Lee JO; Kim TM; Lee SH; Kim DW; Kim S; Jeon YK; Chung DH; Kim WH; Kim YT; Yang SC; Kim YW; Heo DS; Bang YJ
    J Thorac Oncol; 2011 Sep; 6(9):1474-80. PubMed ID: 21642865
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Use of maximum standardized uptake value on fluorodeoxyglucose positron-emission tomography in predicting lymph node involvement in patients with primary non-small cell lung cancer.
    Muto J; Hida Y; Kaga K; Ohtaka K; Okamoto S; Tamaki N; Nakada-Kubota R; Hirano S; Matsui Y
    Anticancer Res; 2014 Feb; 34(2):805-10. PubMed ID: 24511016
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunohistochemical screening for anaplastic lymphoma kinase (ALK) rearrangement in advanced non-small cell lung cancer patients.
    Park HS; Lee JK; Kim DW; Kulig K; Kim TM; Lee SH; Jeon YK; Chung DH; Heo DS
    Lung Cancer; 2012 Aug; 77(2):288-92. PubMed ID: 22465695
    [TBL] [Abstract][Full Text] [Related]  

  • 40. EGFR gene copy number in adenocarcinoma of the lung by FISH analysis: investigation of significantly related factors on CT, FDG-PET, and histopathology.
    Park EA; Lee HJ; Kim YT; Kang CH; Kang KW; Jeon YK; Goo JM; Lee CH; Park CM
    Lung Cancer; 2009 May; 64(2):179-86. PubMed ID: 18819724
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.